Journal of Clinical Endocrinology & Metabolism, Vol 57, 529-536, Copyright © 1983 by Endocrine Society

ARTICLES

Insulin resistance in Cushing's syndrome

R Nosadini, S Del Prato, A Tiengo, A Valerio, M Muggeo, G Opocher, F Mantero, E Duner, C Marescotti, F Mollo and F Belloni

It is well established that cortisol excess causes insulin resistance in man, but the mechanisms responsible for this insulin resistance are poorly understood. We studied five women with Cushing's syndrome with impaired oral glucose tolerance tests and seven normal subjects, plotting the shape of the insulin-induced disposal dose-response curve obtained by means of the euglycemic clamp procedure during four different plasma insulin plateaus at four infusion rates of 21, 73, 760, and 1200 mU/M2 . min. Glucose disposal (M = mg/M2 . min) was calculated as glucose amount infused to maintain euglycemia. In Cushing's syndrome the dose-response curve was shifted to the right in comparison with normal subjects, with a significantly lower M (337 +/- 35 vs. 657 +/- 76 P less than 0.01) during the highest insulin infusion rate [maximal glucose disposal (MGD)] without any significant difference in the levels of insulin half-maximally effective in the stimulation of glucose utilization. Neither erythrocyte nor monocyte maximum insulin receptor binding were different between the two populations. Four Cushing's syndrome patients were studied again after surgical treatment. A marked improvement of MGD was observed without any significant change in insulin-binding capacity. These results, particularly the marked decrease in MGD, a typical feature of postreceptor defects, indicate that cortisol-induced insulin resistance in man is due to an impairment of peripheral insulin action located beyond the hormone-receptor binding step.

This article has been cited by other articles:

				A. Hermanowski-Vosatka, J. M. Balkovec, K. Cheng, H. Y. Chen, M. Hernandez, G. C. Koo, C. B. Le Grand, Z. Li, J. M. Metzger, S. S. Mundt, et al. 11{beta}-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice J. Exp. Med., August 15, 2005; 202(4): 517 - 527. [Abstract] [Full Text] [PDF]

				J. Rosen and J. N. Miner The Search for Safer Glucocorticoid Receptor Ligands Endocr. Rev., May 1, 2005; 26(3): 452 - 464. [Abstract] [Full Text] [PDF]

				M. Lundgren, J. Buren, T. Ruge, T. Myrnas, and J. W. Eriksson Glucocorticoids Down-Regulate Glucose Uptake Capacity and Insulin-Signaling Proteins in Omental But Not Subcutaneous Human Adipocytes J. Clin. Endocrinol. Metab., June 1, 2004; 89(6): 2989 - 2997. [Abstract] [Full Text] [PDF]

				M F. DALLMAN, S F AKANA, A M STRACK, K S SCRIBNER, N PECORARO, S E LA FLEUR, H HOUSHYAR, and F GOMEZ Chronic Stress-Induced Effects of Corticosterone on Brain: Direct and Indirect Ann. N.Y. Acad. Sci., June 1, 2004; 1018(1): 141 - 150. [Abstract] [Full Text] [PDF]

				M. F. Nielsen, A. Caumo, V. Chandramouli, W. C. Schumann, C. Cobelli, B. R. Landau, H. Vilstrup, R. A. Rizza, and O. Schmitz Impaired basal glucose effectiveness but unaltered fasting glucose release and gluconeogenesis during short-term hypercortisolemia in healthy subjects Am J Physiol Endocrinol Metab, January 1, 2004; 286(1): E102 - E110. [Abstract] [Full Text]

				M. Haluzik, K. R. Dietz, J. K. Kim, B. Marcus-Samuels, G. I. Shulman, O. Gavrilova, and M. L. Reitman Adrenalectomy Improves Diabetes in A-ZIP/F-1 Lipoatrophic Mice by Increasing Both Liver and Muscle Insulin Sensitivity Diabetes, July 1, 2002; 51(7): 2113 - 2118. [Abstract] [Full Text] [PDF]

				L. Benthem, K. Keizer, C. H. Wiegman, S. F. de Boer, J. H. Strubbe, A. B. Steffens, F. Kuipers, and A. J. W. Scheurink Excess portal venous long-chain fatty acids induce syndrome X via HPA axis and sympathetic activation Am J Physiol Endocrinol Metab, December 1, 2000; 279(6): E1286 - E1293. [Abstract] [Full Text] [PDF]

				A. Glasow, A. Haidan, U. Hilbers, M. Breidert, J. Gillespie, W. A. Scherbaum, G. P. Chrousos, and S. R. Bornstein Expression of Ob Receptor in Normal Human Adrenals: Differential Regulation of Adrenocortical and Adrenomedullary Function by Leptin J. Clin. Endocrinol. Metab., December 1, 1998; 83(12): 4459 - 4466. [Abstract] [Full Text]

				S. R. Bornstein, E. L. Webster, D. J. Torpy, S. J. Richman, N. Mitsiades, M. Igel, D. B. Lewis, K. C. Rice, H. G. Joost, M. Tsokos, et al. Chronic Effects of a Nonpeptide Corticotropin-Releasing Hormone Type I Receptor Antagonist on Pituitary-Adrenal Function, Body Weight, and Metabolic Regulation Endocrinology, April 1, 1998; 139(4): 1546 - 1555. [Abstract] [Full Text] [PDF]